(Q38088216)

28 August 2017

title

Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management (English)

1 reference

28 August 2017

0 references

1 reference

1 reference

Joe M Chehade

1

1 reference

28 August 2017

Margaret Gladysz

series ordinal

2

1 reference

28 August 2017

Arshag D Mooradian

series ordinal

3

1 reference

28 August 2017

language of work or name

1 reference

1 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

73

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

327-339

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0023-5

28 August 2017

exact match

0 references

cites work

The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Dyslipidemia in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Cardiovascular disease in type 2 diabetes mellitus: current management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Familial dyslipidaemias: an overview of genetics, pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Prevalence and control of dyslipidemia among persons with diabetes in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg/dl and non-high-density lipoprotein cholesterol <80 mg/dl

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Gender and racial differences in lipoprotein subclass distributions: the STRRIDE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Transcriptional control of apolipoprotein A-I gene expression in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

A rational approach to drug therapy of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Reduced plasma high density lipoprotein-cholesterol concentrations need not increase when hyperglycemia is controlled with insulin in noninsulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Approach to lipoprotein management in 2001 National Cholesterol Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Effect of low and high fat diets on nutrient intakes and selected cardiovascular risk factors in sedentary men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Exercise is required for visceral fat loss in postmenopausal women with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Changes in high-density lipoprotein-cholesterol subfractions with exercise training may be dependent on cholesteryl ester transfer protein (CETP) genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

High-density lipoprotein-cholesterol, its subfractions, and responses to exercise training are dependent on endothelial lipase genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Ezetimibe: cholesterol lowering and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Simvastatin with or without ezetimibe in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment dura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Autonomic function, omega-3, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0023-5

Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association

21 January 2018

1 reference

12 December 2020

U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex

1 reference

12 December 2020

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

1 reference

12 December 2020

Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial

1 reference

12 December 2020

Obesity: a rational target for managing diabetes mellitus

1 reference

12 December 2020

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study

1 reference

12 December 2020

American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

1 reference

12 December 2020

Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico

1 reference

12 December 2020

Diabetic dyslipidemia

1 reference

12 December 2020

Changes in inflammatory biomarkers after successful lifestyle intervention in obese children

1 reference

12 December 2020

Low serum high-density lipoprotein cholesterol in obese subjects with normal serum triglycerides: the role of insulin resistance and inflammatory cytokines

1 reference

12 December 2020

Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials

1 reference

12 December 2020

10.1007/S40265-013-0023-5

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1046690074

0 references

1 reference